Emergent advances leukemia therapy to next trial stageGazette.Net: Maryland Community News OnlineThe trial, which will enroll about 24 patients who have not been treated for chronic lymphocytic leukemia, is designed to test the safety and efficacy of T…
Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine …Sacramento BeeThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized contro…
Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine …The Herald | HeraldOnline.comThe European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing ra…
OncLiveSmall-Molecule Inhibitors Hold Promise for Elderly CLL PatientsOncLiveWierda noted that a phase II study is currently under way for patients ≥65 years with previously untreated CLL who will receive GS-1101 in combination with rituximab versus …
Survey: Many docs will be slow to switch to biosimilar mAbsFierceBiotechBut there was a distinct hesitancy noted in the U.S. when the conversation turned to the first generation of biosimilars for the monoclonal antibodies like rituximab (Roche's (…
Cambridge NewsCan you help save Zoe's life?Cambridge NewsDoctors are currently treating Zoe with anti-thymocyte globulin (ATG) – an infusion of horse antibodies. However, it will be four months before Zoe will learn whether this has been successf…
Benlysta will be lupus market leader in 2021 with sales of more than $1.7 …The Pharma LetterThe off-label use of two high-priced agents – the biologic rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera) and the immu…
Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third QuarterBusiness Wire (press release)Approved and investigational therapies in Biogen Idec's MS franchise presented at the conference included BG-12, daclizumab-HYP, anti-LINGO, TY…
Out of the Red and into the Black: John McCamant on Investment inJutia GroupWe have seen Celgene Corp. (CELG:NASDAQ) target multiple myeloma with Revlimid (lenalidomide), and we've seen other drugs in this space, such as Genentech/Roche Holding AG&…
Biogen Idec Management Discusses Q3 2012 Results – Earnings Call TranscriptSeeking AlphaIn a second latebreaking presentation at ECTRIMS, we highlighted primary efficacy results from SELECTION, the one-year extension study of SELECT, the first registra…